BridgeMD
New treatment option for Alcohol Use Disorder
Official title Social Cognition in Severe Alcohol Use Disorder
ClinicalTrials.gov ID: NCT07464613
What this study is testing
- What it's testing
- With 41,000 deaths per year, alcohol consumption is the second leading cause of preventable mortality in France. Nearly 3.4% of adults engage in excessive and chronic alcohol use, meeting criteria for Severe Alcohol Use Disorder (SAUD).
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65. Healthy volunteers may be eligible.
You may be able to join if
- AUD patients
- Patients between 18 and 65 years old, men or women, right-handed, following AUD treatment as inpatients or outpatients and currently abstinent
- Having a diagnosis of severe alcohol use disorder according to DSM-5 criteria
- Native French speakers
- Patients enrolled in the national healthcare insurance program
You likely can't join if
- A diagnosis of schizophrenia, of any other chronic psychotic state, or of bipolar disorder according to DSM-5 criteria
- The presence of a current depressive episode as defined by DSM-5 criteria
- The presence of another moderate or severe substance use disorder according to DSM-5 criteria, except for tobacco and cannabis if alcohol is the...
- The presence of a neurodevelopmental disorder
- The presence of any clinically significant or unstable pathology: organic pathology affecting the central nervous system or disease likely to...
- Having any uncorrected auditory or visual deficits
See the full eligibility criteria
- AUD patients
- Patients between 18 and 65 years old, men or women, right-handed, following AUD treatment as inpatients or outpatients and currently abstinent
- Having a diagnosis of severe alcohol use disorder according to DSM-5 criteria
- Native French speakers
- Patients enrolled in the national healthcare insurance program
- Patients consenting to participate in the study
- A diagnosis of schizophrenia, of any other chronic psychotic state, or of bipolar disorder according to DSM-5 criteria
- The presence of a current depressive episode as defined by DSM-5 criteria
- The presence of another moderate or severe substance use disorder according to DSM-5 criteria, except for tobacco and cannabis if alcohol is the primary substance consumed and the criteria for cannabis dependence are...
- The presence of a neurodevelopmental disorder
- The presence of any clinically significant or unstable pathology: organic pathology affecting the central nervous system or disease likely to interfere with assessments, including the neurological complications of...
- Having any uncorrected auditory or visual deficits
- Contraindication to the use of MRI
- Individuals particularly protected by the law
- No smartphone with Apple or Android operating system
- Healthy control participants: Inclusion criteria:
- Participants between 18 and 65 years old, men or women, right-handed
- Native French speakers
- Participants enrolled in the national healthcare insurance program
- Participants consenting to participate in the study Exclusion criteria:
- A diagnosis of schizophrenia, of any other chronic psychotic state, or of bipolar disorder according to DSM-5 criteria
- The presence of a current depressive episode as defined by DSM-5 criteria
- The presence of substance use disorder as defined by DSM-5 diagnostic criteria, except for tobacco dependence
- Having any first-degree relative with alcohol use disorder according to DSM-5 diagnostic criteria
- The presence of a neurodevelopmental disorder
- The presence of any clinically significant or unstable pathology: organic pathology affecting the central nervous system
- Having any uncorrected auditory or visual deficits
- Contraindication to the use of MRI
- Individuals particularly protected by the law
- No smartphone with Apple or Android operating system
The study team makes the final eligibility decision.
Where it's taking place
- Reims, Reims, France
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Reims, Reims, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.